CCR5 antagonist maraviroc's effect to osteoclasts in human

CCR5 antagonist maraviroc's effect to osteoclasts in human - MVC Bone Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006266

Enrollment

Registered

2011-09-01

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV-1 infection, AIDS

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those who met all folowing criteria: - Those whose primary care physician acknowledged the necessity of maraviroc treatment (had multi-resistance HIV strain confirmed to be CCR5 tropic). - Those who are willing and able to consent to this study - 20 years old or older

Exclusion criteria

Exclusion criteria: - Those who are not suited for maraviroc (whose HIV strain to be CXCR4 tropism) - Others who the principle investigator physician considered to be excluded

Design outcomes

Primary

Measure	Time frame
Bone metabolism and density evaluation by - Bone and chemokine markers (DPD, NTX, CTX, TRACP, BAP, osteocalcin, MIP-1alpha, MIP-1beta and RANTES) and - DEXA	—

Secondary

Measure	Time frame
- Other infections: HBV, HCV, RPR, TPHA - HIV treatment markers: CD4, CD8, CD4/CD8, HIV-RNA - HAART regimens and start dates - Other medications: antibiotics, anticoagulants, antiplatelets, NSAID, steroids - Past medical history - HIV risk behaviors, age, sex	—

Countries

Japan

Contacts

Public ContactFumihide Kanaya

National Center for Global Health and Medicine AIDS Clinical Center

fkanaya@yahoo.com03-5273-5277

Outcome results